Morningstar2d
Eli Lilly and Co
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...
BioSpace4d
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Yahoo Finance4d
Eli Lilly and Co (LLY) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
The company achieved a 45% revenue growth in Q4 2024, driven by strong performance of new products like Mounjaro and Zepbound. Eli Lilly and Co (NYSE:LLY) advanced its pipeline with positive Phase ...
Eli Lilly & Co. stock underperforms Monday when compared to competitors
The stock's fall snapped a four-day winning streak.
Eli Lilly & Co (LLY) Gets a Buy from Citi
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...
clinicaltrialsarena6d
Lilly’s investigational Alzheimer’s to be investigated in prevention trial
The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...